ATE496921T1 - Isoflavonoiddimere - Google Patents

Isoflavonoiddimere

Info

Publication number
ATE496921T1
ATE496921T1 AT06721277T AT06721277T ATE496921T1 AT E496921 T1 ATE496921 T1 AT E496921T1 AT 06721277 T AT06721277 T AT 06721277T AT 06721277 T AT06721277 T AT 06721277T AT E496921 T1 ATE496921 T1 AT E496921T1
Authority
AT
Austria
Prior art keywords
isoflavonoid
dimers
treatment
compounds
isoflavonoid dimers
Prior art date
Application number
AT06721277T
Other languages
English (en)
Inventor
Andrew Heaton
Naresh Kumar
Original Assignee
Novogen Res Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005901475A external-priority patent/AU2005901475A0/en
Application filed by Novogen Res Pty Ltd filed Critical Novogen Res Pty Ltd
Application granted granted Critical
Publication of ATE496921T1 publication Critical patent/ATE496921T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pyrane Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06721277T 2005-03-24 2006-03-24 Isoflavonoiddimere ATE496921T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2005901475A AU2005901475A0 (en) 2005-03-24 Isflavonoid dimers
US66860905P 2005-04-06 2005-04-06
AU2005905985A AU2005905985A0 (en) 2005-10-28 Pain and anti-inflammatory modalities
PCT/AU2006/000395 WO2006099681A1 (en) 2005-03-24 2006-03-24 Isoflavonoid dimers

Publications (1)

Publication Number Publication Date
ATE496921T1 true ATE496921T1 (de) 2011-02-15

Family

ID=37023310

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06721277T ATE496921T1 (de) 2005-03-24 2006-03-24 Isoflavonoiddimere

Country Status (15)

Country Link
US (3) US20090131513A1 (de)
EP (3) EP1861090A4 (de)
JP (2) JP2008533177A (de)
CN (2) CN101203219B (de)
AT (1) ATE496921T1 (de)
AU (2) AU2006227555A1 (de)
CA (2) CA2602549A1 (de)
DE (1) DE602006019832D1 (de)
ES (1) ES2360130T3 (de)
HK (1) HK1119557A1 (de)
IL (2) IL186217A0 (de)
MX (1) MX2007011493A (de)
NO (2) NO20075367L (de)
NZ (2) NZ561573A (de)
WO (2) WO2006099681A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029995A1 (ja) * 2008-09-11 2010-03-18 協和発酵キリン株式会社 疼痛治療剤
JP6115303B2 (ja) * 2012-05-18 2017-04-19 Jnc株式会社 隣接基としてカルボニル基を有するフェノール化合物およびその用途
KR101539180B1 (ko) * 2014-09-18 2015-07-24 성균관대학교산학협력단 플라보노이드계 화합물을 포함하는 림프부종의 예방 또는 치료용 조성물
KR101533197B1 (ko) * 2014-09-18 2015-07-02 성균관대학교산학협력단 부테인을 포함하는 부종의 예방 또는 치료용 조성물
WO2016153937A1 (en) 2015-03-20 2016-09-29 Stanford University Carbonate-promoted carboxylation reactions for the synthesis of valuable organic compounds
US11559510B2 (en) 2016-04-06 2023-01-24 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
US11229703B2 (en) 2016-04-06 2022-01-25 Noxopharm Limited Radiotherapy improvements
RU2649119C1 (ru) * 2017-02-27 2018-03-29 Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук (ИрИХ СО РАН) Средство для профилактики и лечения язвенного колита
WO2019051548A1 (en) * 2017-09-15 2019-03-21 Norbio No. 2 Pty Ltd TREATMENT OF NEURO-INFLAMMATION
WO2020051644A1 (en) * 2018-09-13 2020-03-19 Norbio No. 2 Pty Ltd Treatment of peripheral nervous tissue inflammation
WO2021195698A1 (en) * 2020-03-30 2021-10-07 Noxopharm Limited Methods for the treatment of inflammation associated with infection
JP2023519990A (ja) 2020-03-30 2023-05-15 ノクソファーム リミティド 感染に関連する炎症の治療のための方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967362A (ja) * 1995-09-01 1997-03-11 Sankyo Co Ltd ５α−還元酵素阻害剤ビスイソフラボン類
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
ES2244091T3 (es) * 1997-11-11 2005-12-01 Nikken Chemicals Company, Limited Derivado de n-hidroxiurea y composicion farmaceutica que lo contiene.
US6518301B1 (en) * 1999-04-16 2003-02-11 Astrazeneca Ab Estrogen receptor-β ligands
AUPQ266199A0 (en) * 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
JP2004521856A (ja) * 2000-05-15 2004-07-22 メルク フロスト カナダ アンド カンパニー Ｃｏｘ−２選択的阻害剤およびトロンボキサン阻害剤を用いる併用療法ならびにそのための組成物
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
WO2002074307A1 (en) * 2001-03-16 2002-09-26 Novogen Research Pty Ltd Treatment of restenosis
CN1398586A (zh) * 2001-07-26 2003-02-26 中国人民解放军军事医学科学院放射医学研究所 新的取代庚酸衍生物治疗支气管哮喘和慢性阻塞性肺病
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
AU2002952453A0 (en) * 2002-11-01 2002-11-21 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof
JP2007525485A (ja) * 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法
EP2407462B1 (de) * 2004-09-21 2014-07-30 Marshall Edwards, Inc. Substituierte Chromanderivate, Medikamente und therapeutische Verwendung

Also Published As

Publication number Publication date
AU2006235194A1 (en) 2006-10-19
HK1119557A1 (en) 2009-03-13
EP1861090A4 (de) 2010-01-06
AU2006227555A1 (en) 2006-09-28
WO2006108212A1 (en) 2006-10-19
NZ561573A (en) 2010-05-28
EP1861090A1 (de) 2007-12-05
NO20075368L (no) 2007-12-11
CA2602549A1 (en) 2006-10-19
MX2007011493A (es) 2008-04-14
CN101184756A (zh) 2008-05-21
CA2602541A1 (en) 2006-09-28
US20090131513A1 (en) 2009-05-21
NZ561574A (en) 2010-03-26
US7700644B2 (en) 2010-04-20
CN101203219B (zh) 2011-06-15
EP1861402B1 (de) 2011-01-26
JP2008533177A (ja) 2008-08-21
IL186218A0 (en) 2008-01-20
IL186217A0 (en) 2008-08-07
NO20075367L (no) 2007-11-27
US20120059176A1 (en) 2012-03-08
EP1861402A1 (de) 2007-12-05
WO2006099681A1 (en) 2006-09-28
ES2360130T3 (es) 2011-06-01
US20080306140A1 (en) 2008-12-11
EP1861402A4 (de) 2009-12-30
CN101184756B (zh) 2011-08-03
EP2526941A1 (de) 2012-11-28
JP2008537545A (ja) 2008-09-18
DE602006019832D1 (de) 2011-03-10
CN101203219A (zh) 2008-06-18

Similar Documents

Publication Publication Date Title
ATE496921T1 (de) Isoflavonoiddimere
NL300936I2 (nl) Semaglutide
CR20130455A (es) Composiciones para el tratamiento de tumores
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
NO20081636L (no) FAP - inhibitorer
DOP2009000134A (es) Compuestos bicíclicos y su uso como anti-diabéticos
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
DE602005017746D1 (de) Zusammensetzungen mit fluorsubstituierten olefinen
EA201101085A1 (ru) Феноксиуксусные кислоты в качестве активаторов ppar дельта
BRPI0607379B8 (pt) composição farmacêutica de efeito analgésico
ATE471324T1 (de) Triazolophthalazine
EA200601884A1 (ru) Бета-карболины, применяемые для лечения воспалительных заболеваний
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
CY1113916T1 (el) Παραγωγα ετεροαρυλο πυρρολιδινυλο και πιπεριδινυλο κετονης
CY1109992T1 (el) Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
CL2008003602A1 (es) Compuestos derivados de triazolotriazinas y triazolopirazinas sustituidas; composicion farmaceutica; y su uso en el tratamiento y/o profilaxis de trastornos hematologicos.
DK1951274T3 (da) Parapoxvirusser i kombination med klasssiske cytotoksiske kemoterapeutiske midler som biokemoterapi til behandling af cancer
ATE527996T1 (de) Medizinische verwendung von 3-(2,2,2- trimethylhydrazinium)propionat-orotat
EA200701366A1 (ru) Кислородсодержащие аннелированные фенилпиперазин- и фенилдиазепанкарбоксамиды
ATE526968T1 (de) Zusammensetzungen zur behandlung von vaginalen infektionen mit chronischer entzündung
DE112006002215A5 (de) Proteinzusammensetzung zur Behandlung von Proteinmangelzuständen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties